Clinical Trial

Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin A(IgA) nephropathy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-03-07; most recent amendment 2024-10-14.
Status change: Not Yet Recruiting → Recruiting 2023-07-27
Trial Details
NCT Number NCT05775042
Lead Sponsor Keymed Biosciences Co.Ltd
Conditions IgA Nephropathy
Enrollment 70 participants
Start Date 2023-05-08
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-15